One of the most important things to do when suffering from multiple sclerosis, especially if the patient has secondary progressive multiple sclerosis, is to try and prevent the worsening of the disease. Till some recent time ago this was not possible; it was almost impossible to do anything about it if the disease had entered the secondary progressive stage.

In their battle against the disease the scientist have just completed a research program in Europe based on a randomized double blind placebo trial. Using interferon 1-b on patients, on a bases if administering them 8 million units subcutaneously on a daily bases, scientist have come up with some interesting findings and answers to questions. Clinical active secondary progressive patients where also included in the research. Some interesting results showed up after completing the research; this way scientists could see that the delay of the progression was within a range of 9 to 12 months. By applying this treatment to people, doctors actually succeeded in reducing the number of patients that became wheelchair bound, and also increase the time till they became stricken down. The dosage of steroid courses given also drastically reduced, not to mention the fact that the number of admissions to the hospital because of multiple sclerosis where also reduced. Thanks to the research made and the results gotten aft

er this study, interferon 1-b is now available for all patients with multiple sclerosis, significantly improving the life of secondary progressive sufferers.

Researches also done with placebo effects drugs didn't have such effective responses from patients. Conclusive results of the research are yet to be fully explained or published. Also results from a study done in the USA, also with interferon 1-b, are eagerly awaited be patients and a whole other people.

Still some questions regarding the usage of interferon beta in multiple sclerosis people are yet to be answered. It is still unknown when to actually start and stop the administering of interferon beta in secondary progressive cases of the disorder. Results are being reviewed and findings from other researches are also eagerly awaited. The impact of all these findings on the fight against multiple sclerosis are shore to be great.